DE69739907D1 - 3 vermittelter angiogenesis hemmers - Google Patents
3 vermittelter angiogenesis hemmersInfo
- Publication number
- DE69739907D1 DE69739907D1 DE69739907T DE69739907T DE69739907D1 DE 69739907 D1 DE69739907 D1 DE 69739907D1 DE 69739907 T DE69739907 T DE 69739907T DE 69739907 T DE69739907 T DE 69739907T DE 69739907 D1 DE69739907 D1 DE 69739907D1
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- beta
- growth factor
- mediated angiogenesis
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1873396P | 1996-05-31 | 1996-05-31 | |
US1586996P | 1996-05-31 | 1996-05-31 | |
PCT/US1997/009158 WO1997045137A1 (en) | 1996-05-31 | 1997-05-30 | Methods and compositions useful for inhibition of angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69739907D1 true DE69739907D1 (de) | 2010-07-22 |
Family
ID=26687899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739907T Expired - Lifetime DE69739907D1 (de) | 1996-05-31 | 1997-05-30 | 3 vermittelter angiogenesis hemmers |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP0951295B1 (de) |
JP (1) | JP2002515036A (de) |
KR (2) | KR20000016301A (de) |
CN (1) | CN1226254A (de) |
AT (1) | ATE470450T1 (de) |
BR (1) | BR9709514A (de) |
CA (2) | CA2256543C (de) |
CZ (2) | CZ380098A3 (de) |
DE (1) | DE69739907D1 (de) |
DK (1) | DK0951295T3 (de) |
HU (2) | HUP9902099A3 (de) |
NO (2) | NO985574L (de) |
PL (2) | PL330240A1 (de) |
WO (2) | WO1997045137A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063790A1 (en) * | 1996-05-31 | 2004-04-01 | The Scripps Research Institute | Methods for inhibition of angiogenesis |
US7387779B2 (en) | 1998-06-17 | 2008-06-17 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
US6962974B1 (en) | 1998-06-17 | 2005-11-08 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and fragments and methods of use thereof |
US6759047B1 (en) | 1998-06-17 | 2004-07-06 | Beth Israel Deaconess Hospital Corp. | Anti-angiogenic proteins and methods of use thereof |
EA003274B1 (ru) * | 1998-07-14 | 2003-04-24 | Фармация Энд Апджон Компани | Оксазолидиноны в качестве активного вещества при лечении инфекционных глазных болезней |
DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
WO2000047228A1 (en) * | 1999-02-12 | 2000-08-17 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
US6344484B1 (en) | 1999-02-12 | 2002-02-05 | 3-Dimensional Pharmaceuticals, Inc. | Tyrosine alkoxyguanidines as integrin inhibitors |
UA71608C2 (en) * | 1999-03-11 | 2004-12-15 | Merck Patent Gmbh | A method for producing the cyclic pentapeptide |
AU2001258638A1 (en) * | 2000-05-26 | 2001-12-03 | Glaxo Group Limited | Methods for identifying modulators of the interaction between lap (latency associated peptide) and intergrin alpha.v.beta.3 and medical use thereof |
CN1329167A (zh) * | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人非整合蛋白-金属蛋白酶10.67和编码这种多肽的多核苷酸 |
US6486174B2 (en) | 2000-08-07 | 2002-11-26 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
ATE415163T1 (de) | 2000-11-01 | 2008-12-15 | Merck Patent Gmbh | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen |
JP4615826B2 (ja) | 2001-01-29 | 2011-01-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用 |
RU2316337C2 (ru) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
US6872730B2 (en) | 2001-04-27 | 2005-03-29 | 3-Dimensional Pharmaceuticals, Inc. | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
US7019108B2 (en) * | 2001-06-01 | 2006-03-28 | University Of Southern California | Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2 |
BR0211604A (pt) * | 2001-08-01 | 2004-08-24 | Merck Patent Gmbh | Inibidores de integrina para o tratamento de doenças do olho |
DE10159453A1 (de) * | 2001-12-04 | 2003-06-18 | Merck Patent Gmbh | Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease |
GB0217017D0 (en) * | 2002-07-23 | 2002-08-28 | Bioacta Ltd | Peptide 2 |
FR2856598B1 (fr) * | 2003-06-25 | 2005-10-28 | Inst Nat Sante Rech Med | Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale |
US7196061B2 (en) | 2003-09-10 | 2007-03-27 | Wyeth | Compounds that modulate neuronal growth and their uses |
ES2521679T3 (es) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
EP1862541A1 (de) * | 2006-06-01 | 2007-12-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptide abgeleitet von der Hemopexin-ähnlichen Domäne der Metalloproteinase MMP-2 |
EP2101805B1 (de) | 2007-01-18 | 2012-11-07 | Merck Patent GmbH | Integrin-liganden zur verwendung in der behandlung von krebs |
EP2192919A1 (de) * | 2007-08-24 | 2010-06-09 | University Health Network | Verfahren zur hemmung des tumorwachstums mit beta-5-integrin-antagonisten |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
CA2763275A1 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
NZ599899A (en) | 2009-11-10 | 2014-10-31 | Allegro Pharmaceuticals Inc | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
JP6428604B2 (ja) * | 2013-04-04 | 2018-11-28 | 味の素株式会社 | 脱保護方法 |
AU2015314809A1 (en) * | 2014-09-12 | 2017-03-16 | Biogen Ma Inc. | Humanized anti-alpha v beta 5 antibodies and uses thereof |
CN111748041B (zh) * | 2019-03-11 | 2021-09-14 | 中国科学院苏州纳米技术与纳米仿生研究所 | 微环境控释型功能化水凝胶、其制备方法及应用 |
CN116239704B (zh) * | 2023-05-09 | 2023-07-14 | 北京青云智创科技有限公司 | 一种治疗新生血管性眼病的多肽及其制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
EP0844874B1 (de) * | 1995-08-14 | 2005-11-09 | The Scripps Research Institute | VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE |
DE19534177A1 (de) * | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
DE19538741A1 (de) * | 1995-10-18 | 1997-04-24 | Merck Patent Gmbh | Cyclopeptidderivate |
-
1997
- 1997-05-30 JP JP54291497A patent/JP2002515036A/ja not_active Abandoned
- 1997-05-30 KR KR1019980709874A patent/KR20000016301A/ko not_active Application Discontinuation
- 1997-05-30 KR KR1019980709875A patent/KR20000016302A/ko not_active Application Discontinuation
- 1997-05-30 HU HU9902099A patent/HUP9902099A3/hu unknown
- 1997-05-30 AT AT97928698T patent/ATE470450T1/de active
- 1997-05-30 DE DE69739907T patent/DE69739907D1/de not_active Expired - Lifetime
- 1997-05-30 PL PL97330240A patent/PL330240A1/xx unknown
- 1997-05-30 WO PCT/US1997/009158 patent/WO1997045137A1/en not_active Application Discontinuation
- 1997-05-30 DK DK97928698.6T patent/DK0951295T3/da active
- 1997-05-30 CZ CZ983800A patent/CZ380098A3/cs unknown
- 1997-05-30 CZ CZ983834A patent/CZ383498A3/cs unknown
- 1997-05-30 PL PL97330241A patent/PL330241A1/xx unknown
- 1997-05-30 CN CN97196818A patent/CN1226254A/zh active Pending
- 1997-05-30 BR BR9709514A patent/BR9709514A/pt not_active IP Right Cessation
- 1997-05-30 WO PCT/US1997/009099 patent/WO1997045447A1/en not_active Application Discontinuation
- 1997-05-30 HU HU9901628A patent/HUP9901628A3/hu unknown
- 1997-05-30 CA CA2256543A patent/CA2256543C/en not_active Expired - Fee Related
- 1997-05-30 EP EP97928698A patent/EP0951295B1/de not_active Expired - Lifetime
- 1997-05-30 CA CA002256588A patent/CA2256588A1/en not_active Abandoned
- 1997-05-30 EP EP97927814A patent/EP0907661A4/de not_active Withdrawn
-
1998
- 1998-11-27 NO NO985574A patent/NO985574L/no not_active Application Discontinuation
- 1998-11-27 NO NO985575A patent/NO985575L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO985575D0 (no) | 1998-11-27 |
WO1997045137A8 (en) | 2001-02-01 |
HUP9902099A2 (hu) | 1999-09-28 |
DK0951295T3 (da) | 2010-09-13 |
WO1997045447A1 (en) | 1997-12-04 |
NO985575L (no) | 1999-02-01 |
NO985574D0 (no) | 1998-11-27 |
CA2256588A1 (en) | 1997-12-04 |
CA2256543A1 (en) | 1997-12-04 |
JP2002515036A (ja) | 2002-05-21 |
EP0907661A1 (de) | 1999-04-14 |
EP0951295A1 (de) | 1999-10-27 |
WO1997045137A1 (en) | 1997-12-04 |
EP0951295A4 (de) | 2000-07-26 |
CZ380098A3 (cs) | 1999-05-12 |
CZ383498A3 (cs) | 1999-05-12 |
PL330241A1 (en) | 1999-05-10 |
CA2256543C (en) | 2010-12-07 |
HUP9901628A3 (en) | 2002-11-28 |
EP0907661A4 (de) | 2000-07-26 |
BR9709514A (pt) | 1999-08-10 |
KR20000016301A (ko) | 2000-03-25 |
ATE470450T1 (de) | 2010-06-15 |
HUP9902099A3 (en) | 2001-10-29 |
HUP9901628A2 (hu) | 1999-08-30 |
EP0951295B1 (de) | 2010-06-09 |
KR20000016302A (ko) | 2000-03-25 |
NO985574L (no) | 1999-02-01 |
PL330240A1 (en) | 1999-05-10 |
CN1226254A (zh) | 1999-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69739907D1 (de) | 3 vermittelter angiogenesis hemmers | |
ZA966886B (en) | Methods and compositions useful for inhibition of alphavbeta5 mediated | |
MX9604145A (es) | Metodos y composiciones utiles para la inhibicion de angiogenesis. | |
ATE254111T1 (de) | Pyrimidin-derivate als interleukin inhibitoren | |
MY119778A (en) | Androstenone derivative. | |
DE69231513T2 (de) | Pyrimidinyl-Essigsäureamide als Elastase Inhibitoren | |
MX9302219A (es) | Cetonas heterociclicas. | |
DE69805846T2 (de) | Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom | |
TR199802060T2 (xx) | Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�. | |
ATE142640T1 (de) | Triterpenderivate und diese enthaltende endothelinrezeptor antagonisten | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
DE69726281D1 (de) | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält | |
MA23755A1 (fr) | Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires | |
FR2745719B1 (fr) | Composition pour le traitement d'affections cutanees | |
ITPN980034U4 (it) | Sistema di aspirazione che permette di mantenere inalterato il buon odore nei bagni o toilette durante e dopo l'uso del vaso | |
IT218963Z2 (it) | Struttura di muretto artificiale, opportunamente attrezzato, particolarmente per l'arredamento di giardini, parchi e terrazzi | |
ITMI910173A1 (it) | Gancio regolabile per l'appendimento e l'assestamento di mobili pensili |